Next Article in Journal
Prevalence of Thrombophilic Gene Polymorphisms in an Azari Population of Iran
Previous Article in Journal
Intracranial Hemorrhage in Patient Treated with Rivaroxaban
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

TET2 Promoter DNA Methylation and Expression Analysis in Pediatric B-Cell Acute Lymphoblastic Leukemia

by
Ewa Musialik
1,*,
Mateusz Bujko
1,
Agnieszka Wypych
2,
Michał Matysiak
2 and
Janusz Aleksander Siedlecki
1
1
Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, W.K. Roentgena 5, 02-781 Warsaw, Poland
2
Department of Pediatric Haematology and Oncology, Medical University of Warsaw, 02-091 Warszawa, Poland
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2014, 6(1), 5333; https://doi.org/10.4081/hr.2014.5333
Submission received: 31 January 2014 / Revised: 28 February 2014 / Accepted: 24 March 2014 / Published: 28 March 2014

Abstract

TET2 is a novel tumor suppressor gene involved in several hematological malignancies of myeloid and lymphoid origin. Besides loss-of-function mutations and deletions, hypermethylation of the CpG island at the TET2 promoter was found in human cancer. Previous analysis revealed no TET2 mutations in acute lymphoblastic leukemia (ALL). Since the TET2 promoter methylation status in pediatric ALL has not been reported, the aim of the present study was to determine if promoter hypermethylation may be a mechanism of TET2 inactivation in a group of pediatric ALL cases. Methylation of TET2 promoter region in one (1/45) ALL B-common patient was detected by methylation specific polymerase chain reaction (PCR) and subsequently analyzed by bisulfite sequencing. We found no correlation between promoter methylation and gene expression, measured by quantitative reverse transcriptase-PCR, however the level of TET2 expression in ALL group was significantly decreased compared to children’s normal peripheral blood mononuclear cells and isolated B-cells. TET2 promoter hypermethylation seems to have limited clinical relevance in childhood B-cell ALL due to its low frequency.
Keywords: TET2; B-cell acute lymphoblastic leukemia; DNA methylation TET2; B-cell acute lymphoblastic leukemia; DNA methylation

Share and Cite

MDPI and ACS Style

Musialik, E.; Bujko, M.; Wypych, A.; Matysiak, M.; Siedlecki, J.A. TET2 Promoter DNA Methylation and Expression Analysis in Pediatric B-Cell Acute Lymphoblastic Leukemia. Hematol. Rep. 2014, 6, 5333. https://doi.org/10.4081/hr.2014.5333

AMA Style

Musialik E, Bujko M, Wypych A, Matysiak M, Siedlecki JA. TET2 Promoter DNA Methylation and Expression Analysis in Pediatric B-Cell Acute Lymphoblastic Leukemia. Hematology Reports. 2014; 6(1):5333. https://doi.org/10.4081/hr.2014.5333

Chicago/Turabian Style

Musialik, Ewa, Mateusz Bujko, Agnieszka Wypych, Michał Matysiak, and Janusz Aleksander Siedlecki. 2014. "TET2 Promoter DNA Methylation and Expression Analysis in Pediatric B-Cell Acute Lymphoblastic Leukemia" Hematology Reports 6, no. 1: 5333. https://doi.org/10.4081/hr.2014.5333

Article Metrics

Back to TopTop